Martin P Hornshaw is the Director of Scientific Marketing at Metabolon Inc., USA. His goal is to educate the public in general as well as scientists specifically as to the power of mass spectrometry based metabolomics. He has many years of experience as a Scientist and of managing scientists working with the ‘mass spec OMICS’ of metabolomics, lipidomics and proteomics as well as clinical and diagnostic applications of mass spectrometry.
Abstract
We have heard much about genomic medicine but genotype does not equate to phenotype. A potential future of effective precision medicine requires not only estimates of lifetime risk of disease but also accurate measurement of phenotype: molecular phenotype. This will enable assessment of disease risk in the near term, disease progress, effect of intervention on disease progression and so on. Precision Metabolomics™ enables measurement of molecular phenotype in the form of the assessment of an individual’s overall metabolism and changes to metabolism, not just specific, discrete metabolite measurements, in samples such as plasma, urine and tissue. When utilized in a ‘systems medicine’ approach metabolomics becomes a powerful indicator of health and disease. A pragmatic systems medicine approach would be to merge genomics data with large scale phenotypic measurements such as metabolomics, proteomics and imaging. The global metabolomics platform developed over the last15 years by metabolon and its use in recent years in population health studies and applying knowledge of metabolism to precision medicine research will be discussed. These areas include diagnosis of inherited metabolic disease, undiagnosed illness, assessment of penetrance, drug toxicity and ‘scientific wellness’.
Proteomics & System Biology
Chemical Proteomics & Profiling Drug Targets
Multiomics for Precision Medicine & Systems Biology